29,572 Shares of Celldex Therapeutics, Inc. $CLDX Purchased by Ellsworth Advisors LLC

Ellsworth Advisors LLC purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 29,572 shares of the biopharmaceutical company’s stock, valued at approximately $958,000.

A number of other institutional investors have also modified their holdings of the company. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 11.5% in the 2nd quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock valued at $355,120,000 after acquiring an additional 983,195 shares during the last quarter. Commodore Capital LP boosted its position in shares of Celldex Therapeutics by 5.1% in the first quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company’s stock worth $85,537,000 after acquiring an additional 131,616 shares during the last quarter. Eversept Partners LP boosted its position in shares of Celldex Therapeutics by 24.6% in the first quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock worth $56,716,000 after acquiring an additional 353,291 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Celldex Therapeutics by 62.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,059,534 shares of the biopharmaceutical company’s stock valued at $33,596,000 after purchasing an additional 407,818 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Celldex Therapeutics by 438.3% in the second quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock valued at $29,347,000 after purchasing an additional 642,171 shares during the period.

Wall Street Analyst Weigh In

CLDX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $64.00 price objective on shares of Celldex Therapeutics in a research note on Friday, October 2nd. Canaccord Genuity Group cut their price target on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Barclays lifted their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. Finally, Cantor Fitzgerald upped their price target on Celldex Therapeutics from $61.00 to $72.00 and gave the stock an “overweight” rating in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $61.92.

Celldex Therapeutics Price Performance

CLDX stock opened at $28.93 on Friday. The firm has a 50 day simple moving average of $36.84 and a 200-day simple moving average of $34.86. Celldex Therapeutics, Inc. has a twelve month low of $22.10 and a twelve month high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -4.17 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.